Comment
doi: 10.1136/bmj.h2993.
Combined immunotherapy improves survival in metastatic melanoma
Affiliations
- PMID: 26036979
- DOI: 10.1136/bmj.h2993
Item in Clipboard
Comment
Combined immunotherapy improves survival in metastatic melanoma
BMJ.
.
No abstract available
Comment on
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31. N Engl J Med. 2015. PMID: 26027431 Free PMC article. Clinical Trial.
Similar articles
-
Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.Nat Rev Clin Oncol. 2015 Aug;12(8):435. doi: 10.1038/nrclinonc.2015.112. Epub 2015 Jun 23. Nat Rev Clin Oncol. 2015. PMID: 26099982 No abstract available.
-
[New hope in metastatic melanoma treatment?].Ann Dermatol Venereol. 2012 Oct;139(10):693-4. doi: 10.1016/j.annder.2012.05.030. Epub 2012 Sep 8. Ann Dermatol Venereol. 2012. PMID: 23122388 French. No abstract available.
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med. 2015 Sep 24;373(13):1270. doi: 10.1056/NEJMc1509660. N Engl J Med. 2015. PMID: 26398077 No abstract available.
-
[Medical therapy of malignant melanoma].Ann Ital Chir. 1989 Jul-Aug;60(4):257-63. Ann Ital Chir. 1989. PMID: 2699710 Review. Italian. No abstract available.
-
The role of nivolumab in melanoma.Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12. Future Oncol. 2018. PMID: 29328782 Review.
Cited by
-
Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022. Front Oncol. 2022. PMID: 35814436 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
